Physiological and clinical aspects in COVID-19
There is a new public health crises threatening globally with the emergence and spread of 2019 novel corona virus (COVID-19) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). In very recent decade we have seen endemic outbreaks in the form of Middle East respiratory syndrome coronavirus (MERS CoV) and severe acute respiratory syndrome related coronavirus (SARS-CoV). Now we again see the emergence of another serious outbreak due to a new strain called the SARS-CoV-2 virus. This SARS-CoV-2 initially presented as pneumonia of unknown etiology with group of symptoms including fever, dry cough and shortness of breath in a cluster of patients in December 2019 Wuhan, China. COVID-19 now has quickly became a health emergency now across worldwide. SARS-CoV-2 is a newly emerging human infectious corona virus that causes COVID-19, now this has been recognized as a pandemic by the World Health Organization (WHO) on 11th March, 2020. Because of the pathogenesis and proliferation pathways of COVID-19 are still unknown the development of vaccine was not developed yet and definitive treatment was not implemented. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed. The world is in emergent need for searching of possible medications for COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
RUDN Journal of Medicine - 24(2020), 3, Seite 201-206 |
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
R. Kodidala Satyanath [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.22363/2313-0245-2020-24-3-201-206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ009094482 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ009094482 | ||
| 003 | DE-627 | ||
| 005 | 20230310014901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22363/2313-0245-2020-24-3-201-206 |2 doi | |
| 035 | |a (DE-627)DOAJ009094482 | ||
| 035 | |a (DE-599)DOAJb4dbbb78e4f94fd78ce1d121c6d45d74 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 100 | 0 | |a R. Kodidala Satyanath |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physiological and clinical aspects in COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a There is a new public health crises threatening globally with the emergence and spread of 2019 novel corona virus (COVID-19) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). In very recent decade we have seen endemic outbreaks in the form of Middle East respiratory syndrome coronavirus (MERS CoV) and severe acute respiratory syndrome related coronavirus (SARS-CoV). Now we again see the emergence of another serious outbreak due to a new strain called the SARS-CoV-2 virus. This SARS-CoV-2 initially presented as pneumonia of unknown etiology with group of symptoms including fever, dry cough and shortness of breath in a cluster of patients in December 2019 Wuhan, China. COVID-19 now has quickly became a health emergency now across worldwide. SARS-CoV-2 is a newly emerging human infectious corona virus that causes COVID-19, now this has been recognized as a pandemic by the World Health Organization (WHO) on 11th March, 2020. Because of the pathogenesis and proliferation pathways of COVID-19 are still unknown the development of vaccine was not developed yet and definitive treatment was not implemented. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed. The world is in emergent need for searching of possible medications for COVID-19. | ||
| 650 | 4 | |a corona virus | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a mers cov | |
| 650 | 4 | |a sars-cov | |
| 650 | 4 | |a therapies | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a J. Sorout |e verfasserin |4 aut | |
| 700 | 0 | |a S. Jayachandra |e verfasserin |4 aut | |
| 700 | 0 | |a A. Gandhi |e verfasserin |4 aut | |
| 700 | 0 | |a S. Kacker |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t RUDN Journal of Medicine |d Peoples’ Friendship University of Russia (RUDN University), 2018 |g 24(2020), 3, Seite 201-206 |w (DE-627)DOAJ000093289 |x 23130261 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2020 |g number:3 |g pages:201-206 |
| 856 | 4 | 0 | |u https://doi.org/10.22363/2313-0245-2020-24-3-201-206 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b4dbbb78e4f94fd78ce1d121c6d45d74 |z kostenfrei |
| 856 | 4 | 0 | |u http://journals.rudn.ru/medicine/article/viewFile/24434/18506 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2313-0245 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2313-0261 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2020 |e 3 |h 201-206 | ||